Activists from the PrEP4ALL Collaboration also published a letter demanding action from the CDC: “It must license its patents protecting the use of Truvada as PrEP for maximum access and competition to benefit people living in the United States,” the letter stated, adding that the CDC “refuses to act in the interest of people living in the United States and enforce these patents against Gilead.”